title: Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine.
abstract: A variety of biophysical techniques have been employed to examine the size and conformational integrity of highly purified hepatitis A virus (HAV) in solution (purified HAV particles are subsequently formalin-inactivated and adsorbed to aluminum salts for use as the vaccine VAQTA). The size of HAV particles was assessed by a combination of electron microscopy, sedimentation velocity, and dynamic light scattering. The effect of ionic strength and temperature on the overall conformational stability of HAV was determined by a combination of intrinsic HAV protein fluorescence, fluorescent probes of both RNA and protein, and UV-visible spectroscopy. A major structural change in HAV occurs near 60 degrees C with the addition of 0.2 M magnesium chloride enhancing the thermal stability of HAV by approximately 10 degrees C. Salt concentrations above 0.2 M, however, decrease the solubility of HAV. The effect of pH on the physical properties of HAV particles was monitored by dynamic light scattering, analytical size exclusion HPLC, and interaction with fluorescent dyes. HAV particles undergo a substantially reversible association/aggregation at pH values below 6 with the concomitant exposure of previously buried hydrophobic surfaces below pH 4. These results are in good agreement with previous studies of HAV thermal stability under extreme conditions in which the irreversible inactivation of the viral particles was measured primarily by the loss of viral infectivity. The wide variety of biophysical measurements described in this work, however, directly monitor structural changes as they occur, thus providing a molecular basis with which to monitor HAV stability during purification and storage.
authors.affiliation: Department of Vaccine Pharmaceutical Research, Merck Research Laboratories, West Point, PA 19486, USA.
authors.forename: D B
authors.initials: DB
authors.lastname: Volkin
authors.forename: C J
authors.initials: CJ
authors.lastname: Burke
authors.forename: K E
authors.initials: KE
authors.lastname: Marfia
authors.forename: C B
authors.initials: CB
authors.lastname: Oswald
authors.forename: B
authors.initials: B
authors.lastname: Wolanski
authors.forename: C R
authors.initials: CR
authors.lastname: Middaugh
mesh_terms: D002851:Chromatography, High Pressure Liquid; D022362:Hepatitis A Vaccines; D017957:Hepatitis A Virus, Human / Q000737:chemistry*; D008027:Light; D008854:Microscopy, Electron; D010316:Particle Size; D012542:Scattering, Radiation; D013050:Spectrometry, Fluorescence; D013056:Spectrophotometry, Ultraviolet; D015164:Vaccines, Inactivated / Q000737:chemistry*; D014761:Viral Hepatitis Vaccines
chemical_list: D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines